Prima BioMed (IMMP) to Post Earnings on Wednesday

Prima BioMed (NASDAQ:IMMP) will likely be releasing its H2 2026 results before the market opens on Wednesday, September 2nd. Analysts expect the company to announce earnings of ($0.0861) per share and revenue of $6.8450 million for the quarter. Parties can check the company’s upcoming H2 2026 earning report page for the latest details on the call scheduled for Sunday, August 30, 2026 at 6:00 PM ET.

Prima BioMed (NASDAQ:IMMP) last issued its quarterly earnings results on Thursday, July 30th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter. The company had revenue of $3.68 million during the quarter.

Prima BioMed Price Performance

Shares of IMMP stock opened at $0.37 on Tuesday. The stock has a 50 day moving average price of $0.40 and a 200 day moving average price of $0.78. Prima BioMed has a 52-week low of $0.29 and a 52-week high of $3.53.

Institutional Inflows and Outflows

A hedge fund recently raised its position in Prima BioMed stock. Jane Street Group LLC grew its holdings in Prima BioMed Ltd (NASDAQ:IMMP) by 14.7% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 51,574 shares of the biotechnology company’s stock after purchasing an additional 6,617 shares during the quarter. Jane Street Group LLC’s holdings in Prima BioMed were worth $91,000 at the end of the most recent reporting period. 2.32% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

IMMP has been the subject of several research analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Prima BioMed in a research report on Friday, July 10th. Maxim Group upgraded shares of Prima BioMed from a “hold” rating to a “buy” rating in a report on Wednesday, June 17th. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $5.50.

Prima BioMed Company Profile

Prima BioMed, trading as IMMP on NASDAQ, is a clinical-stage biotechnology company specializing in the development of immunotherapy products for cancer treatment. The company’s core technology platform centers on targeting the lymphocyte activation gene-3 (LAG-3), a checkpoint receptor that modulates T-cell activity. Prima BioMed’s lead candidate, eftilagimod alpha (IMP321), is a soluble LAG-3 protein designed to enhance antigen-presenting cell function and stimulate a tumor-specific immune response.